{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T04:41:21Z","timestamp":1789706481329,"version":"4.0.1"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T00:00:00Z","timestamp":1745539200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Bengt Ihre Research Fellowship","award":["2023-1"],"award-info":[{"award-number":["2023-1"]}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","award":["Dnr 2020-02002"],"award-info":[{"award-number":["Dnr 2020-02002"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004047","name":"Karolinska Institutet","doi-asserted-by":"publisher","award":["Dnr FoUI-1002495"],"award-info":[{"award-number":["Dnr FoUI-1002495"]}],"id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Statins reduce the risk of inflammatory bowel disease (IBD), however their effect on IBD disease progression is largely unknown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We linked Swedish healthcare registers and performed a nationwide cohort study (2006-2020) of 19\u2005788 adults (\u226518 years) with ulcerative colitis (UC) and 12\u2005582 with Crohn\u2019s disease (CD). Of these, 1733 with UC and 962 with CD were identified as incident statin users after UC or CD diagnosis. After 1:1 propensity score matching, we compared statin users with non-users to estimate the risk of IBD-related surgery, hospitalizations, and disease flares expressed as incidence rates (IRs) and multivariable-adjusted hazard ratios (aHRs) with 95% confidence intervals (CIs). For outcomes with statistically significant estimates, we calculated the numbers needed to treat (NNT).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>During a median follow-up of 3.4 years we observed a reduced risk of IBD-related surgery in statin users (UC, IR: 3.4 [95%CI: 2.1-4.8] per 1000 person-years; CD, IR: 9.2 [6.2-12.2]) compared with non-users in UC (IR: 6.3 [4.2-8.5]; aHR: 0.55 [0.31-0.97]) and CD (IR: 15.4 [11.0-19.7]; aHR: 0.54 [0.33-0.88]). The NNT to avoid one IBD-related surgical event per year of statin treatment were 345 (UC) and 161 (CD). For statin users, the risks of hospitalizations (IR: 17.0 [13.9-20.2]; aHR: 0.68 [0.51-0.91]) and disease flares (IR: 207.4 [193.2-221.6]; aHR: 0.86 [0.77-0.97]) were reduced in UC, but not in CD (IR: 20.3 [15.8-24.9]; aHR: 0.78 [0.56-1.09] and IR: 245.5 [223.9-267.1]; aHR: 1.02 [0.88-1.19]). In UC, NNT for hospitalizations and disease flares were 145 and 15.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Statins were associated with a reduced risk of IBD-related surgery, hospitalizations, and disease flares in patients with UC, and with a reduced risk of IBD-related surgery in patients with CD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ibd\/izaf077","type":"journal-article","created":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T07:54:09Z","timestamp":1743494049000},"page":"2787-2797","source":"Crossref","is-referenced-by-count":15,"title":["Statin Use is Associated with a Less Severe Disease Course In Inflammatory Bowel Disease: A Nationwide Cohort Study 2006-2020"],"prefix":"10.1093","volume":"31","author":[{"given":"Hamed","family":"Khalili","sequence":"first","affiliation":[{"name":"Clinical and Translation Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School , Boston, MA ,","place":["USA"]},{"name":"Division of Gastroenterology, Department of Medicine, Massachusetts General Hospital , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1906-4982","authenticated-orcid":false,"given":"Anders","family":"Forss","sequence":"additional","affiliation":[{"name":"Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet , Stockholm ,","place":["Sweden"]},{"name":"Centre for Digestive Health, Department of Gastroenterology, Dermatovenereology and Rheumatology, Karolinska University Hospital , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"S\u00f6derling","sequence":"additional","affiliation":[{"name":"Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Br\u00f6ms","sequence":"additional","affiliation":[{"name":"Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet , Stockholm ,","place":["Sweden"]},{"name":"Division of Gastroenterology, Department of Specialist Medicine, Danderyd Hospital , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1046-383X","authenticated-orcid":false,"given":"Carl","family":"Eriksson","sequence":"additional","affiliation":[{"name":"Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet , Stockholm ,","place":["Sweden"]},{"name":"Department of Gastroenterology, Faculty of Medicine and Health, \u00d6rebro University , \u00d6rebro ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2252-684X","authenticated-orcid":false,"given":"Jiangwei","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Medical Epidemiology and Biostatistics, Karolinska Institutet , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas F","family":"Ludvigsson","sequence":"additional","affiliation":[{"name":"Department of Medical Epidemiology and Biostatistics, Karolinska Institutet , Stockholm ,","place":["Sweden"]},{"name":"Department of Paediatrics, \u00d6rebro University Hospital , \u00d6rebro ,","place":["Sweden"]},{"name":"Division of Digestive and Liver Disease, Department of Medicine, Columbia University Medical Center , New York, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ola","family":"Ol\u00e9n","sequence":"additional","affiliation":[{"name":"Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet , Stockholm ,","place":["Sweden"]},{"name":"Sachs\u2019 Children and Youth Hospital, Stockholm South General Hospital , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,4,25]]},"reference":[{"issue":"12","key":"2025102715474882600_CIT0001","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1038\/nrgastro.2015.150","article-title":"The global burden of IBD: from 2015 to 2025","volume":"12","author":"Kaplan","year":"2015","journal-title":"Nat Rev Gastroenterol Hepatol."},{"issue":"8","key":"2025102715474882600_CIT0002","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1136\/gutjnl-2012-302362","article-title":"Oral contraceptives, reproductive factors and risk of inflammatory bowel disease","volume":"62","author":"Khalili","year":"2013","journal-title":"Gut."},{"issue":"11","key":"2025102715474882600_CIT0003","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1111\/apt.14606","article-title":"Systematic review with meta-analysis: association between acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs) and risk of Crohn\u2019s disease and ulcerative colitis exacerbation","volume":"47","author":"Moninuola","year":"2018","journal-title":"Aliment Pharmacol Ther."},{"issue":"19","key":"2025102715474882600_CIT0004","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1001\/jama.2015.15629","article-title":"Statins for prevention of cardiovascular disease in adults: evidence report and systematic review for the US Preventive Services Task Force","volume":"316","author":"Chou","year":"2016","journal-title":"JAMA."},{"issue":"1","key":"2025102715474882600_CIT0005","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.molmed.2007.11.004","article-title":"Pleiotropic effects of statin therapy: molecular mechanisms and clinical results","volume":"14","author":"Wang","year":"2008","journal-title":"Trends Mol Med."},{"issue":"9034","key":"2025102715474882600_CIT0006","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/S0140-6736(96)05190-2","article-title":"Statins do more than just lower cholesterol","volume":"348","author":"Vaughan","year":"1996","journal-title":"Lancet."},{"issue":"2\u20133","key":"2025102715474882600_CIT0007","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1007\/s12026-013-8409-8","article-title":"Statins and autoimmunity","volume":"56","author":"Khattri","year":"2013","journal-title":"Immunol Res."},{"issue":"3","key":"2025102715474882600_CIT0008","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1097\/MIB.0000000000000640","article-title":"Potential immunomodulatory effects of statins in inflammatory bowel disease","volume":"22","author":"C\u00f4t\u00e9-Daigneault","year":"2016","journal-title":"Inflamm Bowel Dis."},{"issue":"5","key":"2025102715474882600_CIT0009","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/nri1839","article-title":"Statin therapy and autoimmune disease: from protein prenylation to immunomodulation","volume":"6","author":"Greenwood","year":"2006","journal-title":"Nat Rev Immunol."},{"key":"2025102715474882600_CIT0010","doi-asserted-by":"publisher","first-page":"104469","DOI":"10.1016\/j.phrs.2019.104469","article-title":"Regulatory T cells: Possible mediators for the anti-inflammatory action of statins","volume":"149","author":"Shahbaz","year":"2019","journal-title":"Pharmacol Res."},{"issue":"5","key":"2025102715474882600_CIT0011","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1093\/ecco-jcc\/jjaa235","article-title":"Association between statin use and inflammatory bowel diseases: results from a Swedish, Nationwide, Population-based Case-control Study","volume":"15","author":"Lochhead","year":"2021","journal-title":"J Crohns Colitis."},{"issue":"10","key":"2025102715474882600_CIT0012","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1038\/ajg.2016.233","article-title":"Statins associated with decreased risk of new onset inflammatory bowel disease","volume":"111","author":"Ungaro","year":"2016","journal-title":"Am J Gastroenterol."},{"issue":"102182","key":"2025102715474882600_CIT0013","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.eclinm.2023.102182","article-title":"Statin use and risk of colorectal cancer in patients with inflammatory bowel disease","volume":"63","author":"Sun","year":"2023","journal-title":"EClinicalMedicine."},{"issue":"6","key":"2025102715474882600_CIT0014","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1002\/ibd.21822","article-title":"Statins are associated with reduced use of steroids in inflammatory bowel disease: a retrospective cohort study","volume":"18","author":"Crockett","year":"2012","journal-title":"Inflamm Bowel Dis."},{"issue":"5","key":"2025102715474882600_CIT0015","doi-asserted-by":"publisher","first-page":"e5263","DOI":"10.1371\/journal.pone.0005263","article-title":"Atorvastatin reduces plasma levels of chemokine (CXCL10) in patients with Crohn\u2019s disease","volume":"4","author":"Grip","year":"2009","journal-title":"PLoS One."},{"issue":"7","key":"2025102715474882600_CIT0016","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1038\/bjp.2008.369","article-title":"Use of atorvastatin as an anti-inflammatory treatment in Crohn\u2019s disease","volume":"155","author":"Grip","year":"2008","journal-title":"Br J Pharmacol."},{"issue":"11","key":"2025102715474882600_CIT0017","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1093\/jamia\/ocab165","article-title":"Computational drug repositioning of atorvastatin for ulcerative colitis","volume":"28","author":"Bai","year":"2021","journal-title":"J Am Med Inform Assoc."},{"issue":"4","key":"2025102715474882600_CIT0018","first-page":"A120","article-title":"Atorvastatin decreases Seo Index in patients with short duration of disease in ulcerative colitis: a randomized placebo-controlled clinical trial","volume":"130","author":"Higgins","year":"2006","journal-title":"Gastroenterology."},{"issue":"2021","key":"2025102715474882600_CIT0019","doi-asserted-by":"publisher","first-page":"533","DOI":"10.2147\/CLEP.S314959","article-title":"Nordic health registry-based research: a review of health care systems and key registries","volume":"13","author":"Laugesen","year":"2021","journal-title":"Clin Epidemiol."},{"issue":"4","key":"2025102715474882600_CIT0020","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s10654-019-00511-8","article-title":"The longitudinal integrated database for health insurance and labour market studies (LISA) and its use in medical research","volume":"34","author":"Ludvigsson","year":"2019","journal-title":"Eur J Epidemiol."},{"issue":"4","key":"2025102715474882600_CIT0021","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1080\/00365521.2021.1884894","article-title":"Capturing biologic treatment for IBD in the Swedish Prescribed Drug Register and the Swedish National Patient Register\u2014a validation study","volume":"56","author":"Br\u00f6ms","year":"2021","journal-title":"Scand J Gastroenterol."},{"issue":"9","key":"2025102715474882600_CIT0022","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1080\/00365521.2019.1660799","article-title":"Swedish inflammatory bowel disease register (SWIBREG)\u2014a nationwide quality register","volume":"54","author":"Ludvigsson","year":"2019","journal-title":"Scand J Gastroenterol."},{"issue":"11","key":"2025102715474882600_CIT0023","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s10654-009-9350-y","article-title":"The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research","volume":"24","author":"Ludvigsson","year":"2009","journal-title":"Eur J Epidemiol."},{"issue":"4","key":"2025102715474882600_CIT0024","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1080\/00365521.2020.1740778","article-title":"The use of ICD codes to identify IBD subtypes and phenotypes of the Montreal classification in the Swedish National Patient Register","volume":"55","author":"Shrestha","year":"2020","journal-title":"Scand J Gastroenterol."},{"issue":"1","key":"2025102715474882600_CIT0025","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1080\/00365521.2018.1564361","article-title":"Changes in inflammatory bowel disease subtype during follow-up and over time in 44\u2005302 patients","volume":"54","author":"Everhov","year":"2019","journal-title":"Scand J Gastroenterol."},{"issue":"2","key":"2025102715474882600_CIT0026","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1080\/00365521.2016.1246605","article-title":"Validating inflammatory bowel disease (IBD) in the Swedish National Patient Register and the Swedish Quality Register for IBD (SWIBREG)","volume":"52","author":"Jakobsson","year":"2017","journal-title":"Scand J Gastroenterol."},{"issue":"9","key":"2025102715474882600_CIT0027","doi-asserted-by":"publisher","first-page":"e063117","DOI":"10.1136\/bmjopen-2022-063117","article-title":"Geographical and sociodemographic differences in statin dispensation after acute myocardial infarction in Sweden: a register-based prospective cohort study applying analysis of individual heterogeneity and discriminatory accuracy (AIHDA) for basic comparisons of healthcare quality","volume":"13","author":"Merlo","year":"2023","journal-title":"BMJ Open."},{"issue":"3","key":"2025102715474882600_CIT0028","doi-asserted-by":"publisher","first-page":"e010500","DOI":"10.1136\/bmjopen-2015-010500","article-title":"Time trends in statin utilisation and coronary mortality in Western European countries","volume":"6","author":"Vancheri","year":"2016","journal-title":"BMJ Open."},{"issue":"2","key":"2025102715474882600_CIT0029","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s12664-013-0420-4","article-title":"Randomized clinical trial: atorvastatin versus placebo in patients with acute exacerbation of mild to moderate ulcerative colitis","volume":"33","author":"Dhamija","year":"2014","journal-title":"Indian J Gastroenterol."},{"issue":"2","key":"2025102715474882600_CIT0030","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.intimp.2006.10.013","article-title":"Simvastatin inhibits NF-kappaB signaling in intestinal epithelial cells and ameliorates acute murine colitis","volume":"7","author":"Lee","year":"2007","journal-title":"Int Immunopharmacol."},{"issue":"2","key":"2025102715474882600_CIT0031","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s10620-011-1879-4","article-title":"Simvastatin attenuates intestinal fibrosis independent of the anti-inflammatory effect by promoting fibroblast\/myofibroblast apoptosis in the regeneration\/healing process from TNBS-induced colitis","volume":"57","author":"Abe","year":"2012","journal-title":"Dig Dis Sci."},{"issue":"7758","key":"2025102715474882600_CIT0032","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1038\/s41586-019-1237-9","article-title":"Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases","volume":"569","author":"Lloyd-Price","year":"2019","journal-title":"Nature."},{"issue":"22","key":"2025102715474882600_CIT0033","doi-asserted-by":"publisher","first-page":"530","DOI":"10.3389\/fmicb.2018.00530","article-title":"Gut microbiome associates with lipid-lowering effect of rosuvastatin in vivo","volume":"9","author":"Liu","year":"2018","journal-title":"Front Microbiol."},{"issue":"4","key":"2025102715474882600_CIT0034","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.3389\/fmicb.2019.01947","article-title":"Alterations in gut microbiota by statin therapy and possible intermediate effects on hyperglycemia and hyperlipidemia","volume":"10","author":"Kim","year":"2019","journal-title":"Front Microbiol."},{"issue":"2","key":"2025102715474882600_CIT0035","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1089\/omi.2017.0130","article-title":"Atorvastatin treatment modulates the gut microbiota of the hypercholesterolemic patients","volume":"22","author":"Khan","year":"2018","journal-title":"OMICS."},{"issue":"1","key":"2025102715474882600_CIT0036","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1186\/1471-2458-11-450","article-title":"External review and validation of the Swedish national inpatient register","volume":"11","author":"Ludvigsson","year":"2011","journal-title":"BMC Public Health."},{"issue":"1","key":"2025102715474882600_CIT0037","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1186\/s12911-019-0948-z","article-title":"Validating surgical procedure codes for inflammatory bowel disease in the Swedish National Patient Register","volume":"19","author":"Forss","year":"2019","journal-title":"BMC Med Inform Decis Mak."}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/advance-article-pdf\/doi\/10.1093\/ibd\/izaf077\/63011858\/izaf077.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/31\/10\/2787\/63011858\/izaf077.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/31\/10\/2787\/63011858\/izaf077.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T19:47:55Z","timestamp":1761594475000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/31\/10\/2787\/8120133"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,25]]},"references-count":37,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,4,25]]},"published-print":{"date-parts":[[2025,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izaf077","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10]]},"published":{"date-parts":[[2025,4,25]]}}}